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Abstract 
Propensity score (PS) analysis is increasingly being used in observational studies, 
especially in some cancer studies where randomization is not feasible. This review 
evaluated the use and reporting quality of PS analysis in oncology studies. We searched 
PubMed to identify the use of PS methods in cancer studies (CS) and cancer surgical 
studies (CSS) in major medical, cancer, and surgical journals over time, and critically 
evaluated 33 CS published in top medical and cancer journals in 2014-2015 and 306 
CSS published up to 11/26/2015, without earlier date limits. The quality of reporting in 
PS analysis was evaluated. It was also compared over time and among journals with 
differing impact factors. 50% of the publications with PS analysis from the past decade 
occurred within the past two years. Of the studies critically evaluated, a considerable 
proportion did not clearly provide the variables used to estimate PS (CS 12.1%, CSS 
8.8%), incorrectly included non-baseline variables (CS 3.4%, CSS 9.3%), neglected the 
comparison of baseline characteristics (CS 21.9%, CSS 15.6%), or did not report the 
matching algorithm utilized (CS 19.0%, CSS 36.1%). In CSS, the reporting of the 
matching algorithm improved in 2014-2015 (P = 0.043), and the reporting of variables 
used to estimate PS was better in top surgery journals (P = 0.008). However, there were 
no significant differences for the inclusion of non-baseline variables and reporting of 
comparability of baseline characteristics. The use of PS in cancer studies has 
dramatically increased recently, but there is substantial room for improvement in the 
quality of reporting even in top journals. Herein we have proposed reporting guidelines 
for PS analyses that are broadly applicable to different areas of medical research which 
will allow better evaluation and comparison across studies applying this approach. 
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INTRODUCTION 
Randomized controlled trials are the gold standard in clinical research but are difficult to 
conduct due to many practical considerations, particularly for treatments that include surgical 
interventions. Propensity score (PS) analysis of observational studies is an alternative method 
of estimating causal treatment effects for clinically important questions in observational 
studies, and well-designed observational studies can also help enhance and complement the 
findings of randomized studies [1]. Although it cannot be regarded as a replacement for 
randomized studies, data generated from large observational cohorts have been used to 
evaluate important clinical questions where data from randomized trials are limited or do not 
exist (Black 1996; Silverman 2009) [2, 3]. Observational studies also tend to have lower 
barriers and cost to subject recruitment which may accelerate participation and accrual. 
PS analysis is a causal inference technique for treatment effect estimation in 
observational studies by accounting for the conditional probability of treatment-selection, 
thus allowing for reduction of bias when comparing interventions between treatment arms [4, 
5]. This approach offers researchers the ability to better understand the potential effect of 
medical interventions and treatments. The use of PS analysis has grown dramatically in the 
last decade with wider availability of large databases such as Surveillance, Epidemiology, 
and End Results-Medicare (SEER-Medicare), Centers for Medicare & Medicaid Services 
(CMS), and the National Cancer Data Base (NCDB).  
Despite its practicality, PS analysis also presents analytical and interpretation 
challenges [6-9]. Importantly, the quality of reporting in PS analysis by studies can be 
variable, particularly since there are currently no standard reporting guidelines. Proper 
analyses and reporting can ensure that published results of PS analyses are reproducible, 
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which in recent years has been recognized as a crucial element for high quality research [10]. 
Lack of consistency in reporting study results also has implications for those who plan to 
perform systematic review or meta-analyses [11].   
The purpose of this study was to evaluate the reporting quality of PS analysis in 
cancer and cancer surgical studies by performing a systematic review of publications in top 
medical and surgery journals. We sought to highlight the challenges and issues associated 
with reporting PS analyses, and to investigate evolving trends by publication year.  Finally, 
we aimed to develop a set of reporting guidelines that could be used to help standardize 
future work. 
 
METHODS 
Search Strategy and Study Selection 
A three-part literature search of PS analysis in cancer and cancer surgical studies was 
conducted in the MEDLINE database using PubMed. Two primary cohorts of publications 
were created.  The first cohort of Propensity Score Cancer Studies (CS) was created using a 
systematic search using the key words cancer and propensity score, propensity matched, or 
propensity analysis across the top 10 general medical journals and top 15 cancer journals 
(based on Web of Knowledge impact factors, listing in Supplementary Method, and searched 
on December 28 2015). Articles reported between 2014 and 2015 were identified. Publication 
of comments, meta-analysis, or reviews, and studies not focusing on cancer were excluded. 
The second cohort of Propensity Score Cancer Surgical Studies (CSS) was created with a 
similar search using the same key words but with an additional key word ‘surgery’ among 
5 
 
studies published through November 26 2015, and without date and journal limits (date of 
search: December 11 2015). A broader criteria for CSS cohort would allow us to compare the 
quality of reporting over time and among surgery journals of differing impact factors. Studies 
were eligible for inclusion if their primary question involved surgery among cancer patients, 
including both comparisons between surgical and non-surgical treatment as well as 
comparisons between different types of surgery. Studies that involved quality of life or cost 
burden as the primary outcome, did not have full-text available for review, or were classified 
as comments, meta-analysis, reviews, or protocols were excluded. A third analysis was then 
performed examining time trends of cancer studies and cancer surgical studies utilizing PS 
analysis among high impact journals between 2000 and 2015, using similar search criteria 
applied to the top 10 general medical journals, top 15 cancer journals, and top 15 surgery 
journals.  
Titles and abstracts for all articles were screened in duplicate by two of the authors 
(XIY and PC) to independently render decisions regarding inclusion of each article. When 
consensus could not be reached, the two investigators reconciled the difference through 
reappraisal of the full text or after review by a third investigator (HP). 
Data Extraction 
Articles meeting eligibility criteria were included for data abstraction. Study characteristics 
recorded were cancer type, number of patients enrolled, number and type of treatments, study 
design, study endpoint and analysis, publication date, and journal. PS elements extracted 
included PS methods used in the estimation of treatment effect, variables used in PS 
estimation, whether any non-baseline variables were included, the comparability of baseline 
characteristics in PS analyses, and the total number of subjects included in the matched 
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analysis and matching algorithm utilized (if PS matching study). The evaluation of matching 
algorithm was abstracted, including distance metric (greedy nearest neighbor matching, 
greedy matching within specified caliper distances, greedy matching by digit, greedy 
matching without distance metric specified, and optimal matching), matching ratio, the use of 
replacement, and the method used to assess comparability of baseline characteristics between 
matched groups [12, 13]. The reporting of the assumptions of no unmeasured confounders 
and sufficient overlap in the propensity scores distribution, and goodness-of-fit of the model 
were also abstracted [4, 14, 15]. The reporting of variables used in PS estimation was 
classified as “Yes”, “No”, or “Unclear”. Studies were classified as “Yes” if the variables 
were listed out or clearly defined and were classified as “No” if the variables were neither 
mentioned in text, tables, nor appendices/supplementary materials. Otherwise, the study was 
classified as “Unclear” if the variables were not clearly reported (e.g., the variables were 
reported as “all relevant covariates” or “all covariates potentially predictive of treatment” 
without any clear definition or statement). If the answer of reporting of variables used in PS 
estimation was “No” or “Unclear”, the item whether non-baseline variables were included 
was defined as “Not evaluable”. The reporting of matching algorithm was recorded as “Yes” 
when the method used to form matched sets of subjects was stated (e.g. greedy matching, 
optimal matching). Other aspects such as completeness of follow-up and accuracy of 
endpoint assessment were not taken into consideration. 
Variables related to reporting of PS estimation, comparability of baseline 
characteristics, and matching algorithm were collected and verified by two authors (XIY and 
PC) and then confirmed by a third author (HP). Interrater agreement was assessed for four 
variables (PS methods used in the estimation of treatment effect, cancer type, variables used 
to estimate the PS, and matching algorithm) with sixty randomly selected articles by two data 
extractors XIY and PC separately. The corresponding Cohen’s κ coefficients for these four 
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variables were 0.95, 1.00, 0.82, and 1.00, respectively, which indicated substantial to perfect 
interrater agreement [16]. No important discrepancies were observed.  
Statistical Methods 
Categorical variables for characteristics and reporting of CS and CSS were described with 
frequencies and percentages. Median and interquartile range were used for number of patients 
enrolled. To investigate evolving trends by publication year and reporting quality in 
differently ranked journals, Fisher’s exact tests were used to compare the reporting of CSS 
published on or before 2013 versus 2014/2015, and to compare the reporting quality of top 15 
versus non-top 15 surgery journals from CSS. 95% confidence intervals for difference in 
proportions were also reported. All reported P values were two-sided, and P< 0.05 was 
considered statistically significant. Statistical analysis was performed using R version 3.2.2 
(R Foundation for Statistical Computing, Vienna, Austria). 
 
RESULTS 
Study Selection and Time Trends 
We identified 37 cancer-focused studies involving PS methods reported in top medical/cancer 
journals between 2014 and 2015, of which 33 met the inclusion criteria (18 in JCO, 6 in JNCI, 
4 in BMJ, 3 in The Lancet Oncology, and 2 in JAMA [Fig 1A]). For cancer surgical studies, 
505 citations were identified via PubMed (Fig 1B). 480 articles were selected after screening 
titles and abstracts, and 306 eligible articles were included on the basis of their full text. The 
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most common reason for exclusion among these publications was that the primary question 
did not involve surgery.  
Time trends of cancer studies reporting use of PS analysis between 2000 and 2015 
among the top medical/cancer and surgery journals are presented in Fig 2. The number of 
cancer studies using PS has grown markedly in recent years. The last two years alone 
accounted for more than 50% of the total papers published in the past decade. The top three 
journals were Journal of Clinical Oncology (N = 37), Journal of Thoracic and Cardiovascular 
Surgery (N = 29), and Annals of Surgical Oncology (N = 28). A fairly similar time trend was 
also found in CSS cohort (Supplementary Fig S1) with 172 articles published in 2014 and 
2015 and 134 articles published up through 2013. 
Characteristics of Included Studies 
Table 1 describes the main characteristics of studies reviewed. The top three cancer types in 
CS and CSS were gastrointestinal cancer, followed by lung cancer, then genitourinary cancer. 
CS tended to enroll more patients than CSS, with a median of 4515 (Q1 to Q3, 1392 to 20600) 
versus 699 (Q1 to Q3, 307 to 2783). Among the PS matching papers, 19.0% of CS did not 
mention the proportion of matched sample size, i.e. sample size after matching over sample 
size before matching, while it was only 5.5% for CSS. In addition, the overall matched 
proportion was less than 50% in 8 CS (38.1%) and 115 CSS (52.5%). For the matched 
proportion of the targeted treatment group, see Supplementary Table S2. Most of the articles 
reviewed compared two treatments (97.0% and 90.5%, respectively). There was only one CS 
(3%) involving more than two treatment groups, compared to 29 CSS (9.5%). The 
frequencies of different PS methods (i.e. propensity score matching (PSM), propensity score 
weighting (PSW), propensity score stratification (PSS), covariate adjustment using 
9 
 
propensity score (CAPS) and more than one type of PS methods) as reported across the 
studies are available in Table 1. Overall, 16 CS (48.5%) and 207 CSS (67.6%) utilized PSM; 
6 CS (18.2%) and 21 CSS (6.9%) utilized more than one type of PS methods, for example 
both PSM and PSW. A summary on the study design and the study endpoint and analysis can 
be found in Supplementary Tables S3 and S4. Majority of the articles focused on survival or 
time-to-event outcomes (81.8% and 73.2%, respectively), followed by dichotomous or 
discrete outcomes (18.2% and 31.4%, respectively) and continuous outcomes (3.0% and 
12.7%, respectively). More than one primary outcomes were of interest in some studies, 
therefore the total percentages are over 100. 
Reporting of PS Methodology 
There were 4 CS (12.1%) and 27 CSS (8.8%) that did not provide the variables used in PS 
estimation clearly (Table 2). In addition, 1 CS (3.4%) and 26 (9.3%) CSS incorrectly 
included non-baseline variables. In 32 CS and 275 CSS, which involved PSM, PSW, or PSS 
methods, 7 (21.9%) and 43 (15.6%) of the studies, respectively, did not report the 
comparability of baseline characteristics between treated and untreated subjects in the 
matched, weighted, or stratified sample. For those 25 CS and 232 CSS that did report 
baseline comparisons, 2 CS (8.0%) and 31 CSS (13.4%) found imbalanced characteristics. 
Among the 21 CS and 219 CSS that utilized PSM, 4 CS (19.0%) and 79 CSS (36.1%) did not 
report the matching algorithm. 4 CS (19.0%) and 97 CSS (44.3%) did not report the distance 
metric. The matching ratio was reported by all CS, but not reported in 8 CSS (3.7%). 15 CS 
(71.4%) and 188 CSS (85.8%) did not report whether replacement was used. 16 CS (76.2%) 
and 195 CSS (89.0%) assessed the comparability of baseline characteristics between matched 
groups, while 4 CS (19.0%) and 93 CSS (42.5%) did not clearly state the method used. 13 CS 
(39.4%) and 73 CSS (23.9%) discussed or mentioned the assumption of no unmeasured 
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confounders. 4 CS (12.1%) and 14 CSS (4.6%) described the distribution of propensity scores 
among the compared treatment groups. 1 CS (3.0%) and 28 CSS (9.2%) assessed the 
goodness-of-fit of the PS estimation model, while 2 CS (6.1%) and 14 CSS (4.6%) assessed 
the goodness-of-fit of the outcome model.  
The reporting of matching algorithm in CSS improved in the last two years (P = 0.043) 
(Table 3). However, there were no significant improvements for the reporting of variables 
used (P = 0.226), inclusion of non-baseline variables (P = 0.219), and reporting of 
comparability of baseline characteristics (P = 0.135). The reporting of variables used to 
estimate PS was better in top 15 surgery journals (P = 0.008) (Table 3). However, there were 
no significant differences for the inclusion of non-baseline variables (P = 0.487), reporting of 
comparability of baseline characteristics (P = 0.424), and reporting of matching algorithm (P 
= 0.308). 
 
DISCUSSION 
The number of manuscripts utilizing PS methods in cancer and cancer surgical journals has 
rapidly increased in recent years, likely driven in large part by the increasing availability of 
large databases, such as SEER-Medicare, CMS, and NCDB. In this evaluation of the quality 
of PS reporting in over 300 cancer-related observational studies, we demonstrate that 
essential methodological information is often not reported. Our results indicate that the 
quality of PS reporting in cancer studies requires substantial improvement, even in high-
impact factor journals. Our findings clearly support the need for reporting guidelines for PS 
analyses.  
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Inadequate reporting of PS analyses could have significant consequences on the 
interpretation of a study’s findings, and potentially impact either subsequent research or even 
clinical care. First, the design of future clinical studies and patient management can be 
informed by the results of these large PS analyses. Second, inadequate reporting of variables 
included in the PS model, not reporting the matching algorithm utilized, and inconsistent 
reporting of variables in the method and result sections, represents poor data provenance and 
can result in problems with study reproducibility and interpretation. For example, a 
considerable number of studies included in our analysis, 21.9% CS and 15.6% CSS, did not 
report the comparability of measured baseline characteristics after the application of the PS 
methods, which makes it difficult to judge the appropriateness and effectiveness of the PS 
analysis and its results [17]. Moreover, comparisons of balance among measured baseline 
variables should be performed with proper methods for matched samples [8, 9]. The 
recommended methods to assess the comparability of baseline characteristics between 
matched groups include the standardized difference (< 10%) and the C-statistic (close to 0.5) 
[13, 18]. 
Another area of concern that we identified relates to limited reporting of matched 
sample size proportions. Incomplete matching can bias the research findings, especially when 
a sizable proportion of subjects in the treatment group are excluded after matching. The 
inference of treatment effects derived from a limited subset of subjects can systematically 
differ from the target population for inference, which means that the estimated average 
treatment effect on the treated can be biased. When choosing the best matching algorithm (as 
well as the distance metric, ratio, and the use of replacement), there usually exists a trade-off 
between the bias from sizable sample loss and residual confounding from the inclusion of 
poorly matched subjects [19]. Therefore, the reporting of matched sample size proportions 
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and whether the covariate distribution after matching is subsequently retained for the 
treatment comparison have important implications regarding the interpretation of results.  
Despite the broad usage, PS analysis is limited by its inability to control for 
unmeasured confounders and variables measured with error [14, 15]. However, as we have 
noted in the results section these assumptions were often not reported. Also, a low proportion 
of studies reported the amount of overlap in the propensity scores distributions among the 
matched treatment groups. Sufficient overlap in the distribution of propensity scores among 
the comparison groups is also an important assumption in PS analysis to ensure valid causal 
inference [20-22]. 
Finally, lack of consistency in reporting study methods and results gives rise to 
difficulty in performing systematic reviews or meta-analyses. Prior studies have shown that 
inappropriate and poor reporting can lead to misleading results and can waste valuable 
resources [10, 23-25]. The lack of consistency across the reporting of PS analyses calls for a 
more standardized and reproducible reporting of study methods and results, especially 
considering the dramatic increase in the recent use of these statistical methods in studies of 
cancer patients.  
To improve consistency and reproducibility, we propose a set of guidelines and 
recommendations (a concise list shown in Table 4 with an expanded version in 
Supplementary Table S5) to ensure comprehensive, complete, and clear reporting in PS 
analyses. Based on the systematic review, items that could impact the reproducibility and 
interpretability of a PS analysis were generated. These items were then integrated with the 
STROBE categories for reporting observational studies [26]. We believe that following the 
proposed guidelines should substantially improve the reporting quality of PS analysis. While 
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cancer and cancer surgery studies were used to generate these guidelines because of the 
authors combined expertise and the growing use of PS analyses in the oncology literature in 
recent years (Supplementary Fig S2), the recommendations put forward apply to a broad 
range of observational research. Of these recommendations, perhaps the most important 
include the need to state the specific PS method(s) used, to specify the model used in PS 
estimation including the variables used, to describe comparisons of baseline characteristics, 
and to explicitly specify the method used to form matched sets of subjects, if matching is 
used. The set of guidelines should not be viewed as a comprehensive manual for conducting 
proper statistical analyses using PS methods, but it should be viewed as a tool for consistent 
reporting, reproducibility and interpretation of PS analysis. These guidelines are a first step 
toward improving PS analysis reporting and can be further refined. 
While consistent reporting, reproducibility and interpretation of PS analysis are our 
primary focuses, we would like to highlight a few references related to the proper use of PS 
analysis. A few studies reviewed made comparisons among more than two treatment groups. 
In this instance, special approaches are needed to fit propensity scores. Investigators should, 
for example, use a multinomial logistic regression, a multinomial probit model, or a series of 
binary probits to estimate propensity scores [19, 27]. PS analysis has been occasionally used 
in case-control studies. In this review we have one example of this study design. When 
applying PS analysis to case-control study, the investigator should consider the impact of 
artifactual effect modification and residual confounding on the study findings. More complete 
discussion on this topic can be found in Månsson et al. (2007) [28]. In this paper, the studies 
investigated did not involve the effect of time-varying treatment. If the effect of time-varying 
treatment is of interest, special considerations of time-varying covariates for PS estimation 
will be necessary [29, 30]. When using PSS method, the number of strata should be chosen 
based on an analysis of the rate at which the number of strata should increase with sample 
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size to reduce residual confounding [6]. In general, it has been found that PSW is less prone 
to model misspecification than CAPS [31]. In addition, when the numbers of outcomes are 
low relative to the number of confounders, confounder control through use of PS analysis 
provides less biased and more precise estimated treatment effects than multivariable logistic 
regression [32]. PS analysis allows for the estimation of marginal treatment effect, an average 
effect at the population level, whereas multivariable regression yields conditional treatment 
effect, an average effect at the individual level [33]. When outcomes are binary or time-to-
event in nature, which are of primary interest in most studies in this review, the marginal 
odds ratio or hazard ratio would generally be closer to the null than the conditional effect, 
while the statistical significance of the estimates was usually similar [34-36]. Moreover, Knol 
et al. (2012) offered some suggestions in reporting the effect interaction and modification 
[37]. 
In this study, we analyze the existing oncology literature to develop a set of novel 
guidelines for reporting PS analyses. In an era of rapidly increasing use of PS techniques, 
such guidelines are essential to promote study reproducibility and to responsibly inform 
patient care and future prospective research. This is a large scale study to scrutinize and 
evaluate the reporting of PS analyses. Importantly, the descriptions and analyses of the 
quality of PS reporting are not unique to cancer studies, but our guidelines serve as a 
framework for evaluating the quality of reporting in PS analyses in other areas as well. Our 
reporting guidelines can also serve as an evaluation tool in the peer-review process for 
assessing future research involving PS analysis. Our study closely followed the PRISMA 
checklist as illustrated in Supplementary Table S6. 
Despite notable strengths, our study has some limitations. First, the literature search 
utilized was based only on literature contained within the MEDLINE database and reported 
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in PubMed. However, recent studies have shown that using data sources beyond PubMed has 
only modest impact on the results of systematic reviews [38, 39]. Second, the cancer studies 
in top journals included in this review were limited to those published between 2014 and 
2015. Despite this, the studies included accounted for more than half of the literature utilizing 
PS methods published to date, and represent the most contemporary use of PS methods in the 
current literature.  
In conclusion, propensity score analysis is a statistical technique commonly used to 
estimate causal treatment effects for clinical interventions in observational studies. The use of 
this analytical approach has particularly increased in clinical research involving surgical 
interventions. We find that current reporting is often inadequate and ambiguous, even in high 
impact medical journals. Accordingly, we propose rational reporting guidelines to foster 
transparency, consistency and to facilitate interpretation by readers. The purpose of these 
guidelines is to set forth a comprehensive and clear checklist to maximize the value of 
research that leverages PS techniques. 
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Figure Legends 
Fig 1. Process of literature search (A) cancer studies in top medical and cancer journals (B) 
cancer surgical studies 
Fig 2. Publication trends in cancer studies reporting use of propensity score analysis in high 
impact medical/cancer and surgery journals 
Supplementary Fig S1. Published surgical studies in cancer using propensity score analysis  
Supplementary Fig S2. Publication trends of studies reporting use of propensity score 
analysis in cancer, cardiovascular disease, and diabetes 
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versus 2014/15) and by journal ranking (non-top 15 versus top 15) 
Table 4. Brief guidelines for reporting propensity score analysis 
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cancer surgical studies 
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Table 1. Characteristics of included studies 
  Cancer Studies* Cancer Surgical Studies 
Variables 
     No. of Studies /    
Total No. (%) 
      No. of Studies /     
Total No. (%) 
Cancer type 
  
Gastrointestinal cancer 7/33 (21.2) 118/306 (38.6) 
Lung cancer 7/33 (21.2) 89/306 (29.1) 
Genitourinary cancer 6/33 (18.2) 67/306 (21.9) 
Breast cancer 5/33 (15.2) 20/306 (6.5) 
Thyroid cancer 0 5/306 (1.6) 
Head and neck cancers 0 3/306 (1.0) 
Hematopoietic and lymphoid cancers 3/33 (9.1) 0 
Skin cancer 1/33 (3.0) 0 
Nervous system cancer 0 1/306 (0.3) 
Advanced/metastatic cancer 3/33 (9.1) 0 
Others  1/33 (3.0) 3/306 (1.0) 
No. of treatment groups 
  
2 32/33 (97.0) 277/306 (90.5) 
3 1/33 (3.0) 21/306 (6.9) 
≥4 0 8/306 (2.6) 
No. of patients enrolled    
Median 4515 699 
Q1 to Q3 1392 to 20600 307 to 2783 
Not mentioned 0 3/306 (1.0) 
Propensity score methods type   
Propensity score matching 16/33 (48.5) 207/306 (67.6) 
Propensity score weighting 9/33 (27.3) 20/306 (6.5) 
Propensity score stratification 1/33 (3.0) 27/306 (8.8) 
Covariate adjustment using propensity score 1/33 (3.0) 31/306 (10.1) 
More than one type 6/33 (18.2) 21/306 (6.9) 
The proportion of matched sample size†  
  
<25% 2/21 (9.5) 35/219 (16.0) 
25%-<50% 6/21 (28.6) 80/219 (36.5) 
50%-<75% 3/21 (14.3) 53/219 (24.2) 
75%-<100% 6/21 (28.6) 14/219 (6.4) 
Not mentioned 4/21 (19.0) 12/219 (5.5) 
Only reported the matched sample 0 25/219 (11.4) 
* cancer studies in top medical and cancer journals in 2014/15  
† The reporting of the proportion of matched sample size was evaluated in studies utilizing matching. 
Nine studies were included in both cancer studies and cancer surgical studies. 
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Table 2. Reporting of propensity score analysis in included studies 
  Cancer Studies* Cancer Surgical Studies 
Variables 
     No. of Studies /    
Total No. (%) 
      No. of Studies /     
Total No. (%) 
Variables used to estimate the PS 
  
Yes 29/33 (87.9) 279/306 (91.2) 
No/Unclear 4/33 (12.1) 27/306 (8.8) 
Inclusion of non-baseline variables†  
  
Yes 1/29 (3.4) 26/279 (9.3) 
No 28/29 (96.6) 253/279 (90.7) 
Comparability of baseline characteristics‡ 
  
Yes 25/32 (78.1) 232/275 (84.4) 
No 7/32 (21.9) 43/275 (15.6) 
Matching algorithm§ 
  
Yes 17/21 (81.0) 140/219 (63.9) 
No 4/21 (19.0) 79/219 (36.1) 
Distance metric§   
Greedy nearest neighbor matching 4/21 (19.0) 46/219 (21.0) 
Greedy matching within specified caliper distances 8/21 (38.1) 49/219 (22.4) 
Greedy matching by digit 4/21 (19.0) 19/219 (8.7) 
Greedy matching without distance metric specified 0 18/219 (8.2) 
Optimal matching 1/21 (4.8) 8/219 (3.7) 
Not reported 4/21 (19.0) 79/219 (36.1) 
Matching ratio§   
Yes 21/21 (100) 211/219 (96.3) 
No 0 8/219 (3.7) 
Use of replacement§   
With replacement 1/21 (4.8) 4/219 (1.8) 
Without replacement 5/21 (23.8) 27/219 (12.3) 
Not reported 15/21 (71.4) 188/219 (85.8) 
Method to assess comparability of baseline 
characteristics between matched groups§ 
  
Standardized difference 6/21 (28.6) 31/219 (14.2) 
C-statistic 0 17/219 (7.8) 
Absolute difference   1/21 (4.8) 1/219 (0.5) 
Paired test|| 2/21 (9.5) 20/219 (9.1) 
Independent sample test¶ 3/21 (14.3) 31/219 (14.2) 
Regression 0 2/219 (1.0) 
Assessed but method not reported 4/21 (19.0) 93/219 (42.5) 
Not assessed 5/21 (23.8) 24/219 (11.0) 
Imbalanced baseline characteristics#   
Yes 2/25 (8.0) 31/232 (13.4) 
No 23/25 (92.0) 201/232 (86.6) 
* cancer studies in top medical and cancer journals in 2014/15 
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† The reporting of whether non-baseline variables were included was not evaluable if the answer of 
reporting of variables used to estimate the PS was “No/Unclear”. 
‡ The reporting of comparability of baseline characteristics in PS analyses was evaluated in studies utilizing 
matching, weighting, or stratification. 
§ The reporting was evaluated in studies utilizing matching. 
|| The statistical test for paired or matched sample, e.g. paired t-tests, Wilcoxon signed rank test, and 
McNemar’s test 
¶ The statistical test for independent sample, e.g. unpaired t-tests, Wilcoxon rank sum test, chi-squared test, 
and Fisher’s exact test 
# The reporting of whether baseline characteristics were imbalanced was evaluated in studies reporting 
comparability of baseline characteristics. 
Nine studies were included in both cancer studies and cancer surgical studies. 
 
 
  
26 
 
Table 3. Reporting quality of cancer surgical studies by publication year (on or before 2013 versus 2014/15) and by journal ranking 
(non-top 15 versus top 15)  
 
 Variables 
Cancer Surgical Studies 
P value 
Cancer Surgical Studies 
P value 
On or before 2013 2014/15 Non-Top 15 journals Top 15 journals 
Variables used to estimate the PS 
      
Yes 119 (88.8%) 160 (93.0%) 
0.226 
 208 (88.9%)  71 (98.6%)  
0.008 
No/Unclear 15 (11.2%) 12 (7.0%) 26 (11.1%) 1 (1.4%) 
Difference in proportions (95% CI) - 4.2 (-2.7, 11.8)  - 9.7 (1.7, 14.8)  
Inclusion of non-baseline variables  
      
Yes 8 (6.7%) 18 (11.3%) 
0.219 
 18 (8.7%) 8 (11.3%) 
0.487 
No 111 (93.3%) 142 (88.8%) 190 (91.3%) 63 (88.7%) 
Difference in proportions (95% CI) - 4.5 (-3.3, 11.7)  - 2.6 (-5.1, 13.4)  
Comparability of baseline characteristics  
      
        Yes 95 (80.5%) 137 (87.3%) 
0.135 
 179 (83.3%)  53 (88.3%) 
0.424 
 No 23 (19.5%) 20 (12.7%)  36 (16.7%) 7 (11.7%) 
Difference in proportions (95% CI) - 6.8  (-2.4, 16.4)  - 5.1 (-7.3, 13.8)  
Matching algorithm 
      
        Yes 47 (55.3%) 93 (69.4%) 
0.043 
113 (65.7%) 27 (57.4%) 
0.308 
 No 38 (44.7%) 41 (30.6%)  59 (34.3%) 20 (42.6%) 
Difference in proportions (95% CI) - 14.1 (0.4, 27.6)  - -8.3 (-25.0, 7.7)  
CI = confidence interval 
 
      
 
  
27 
 
Table 4. Brief guidelines for reporting propensity score analysis 
 
  Item No.* Recommendation 
Title and abstract □ 1 Indicate the use of propensity analysis with a commonly used term in the title or 
the abstract 
Methods     
Bias □ 9 Describe how propensity score analysis was used to address bias 
Statistical analyses □ 12 Describe all the analytic methods, including the propensity score methods, e.g. 
PSM, PSW, PSS, CAPS 
 □ 13 Indicate the model used to estimate propensity score 
 □ 14 State the variables included in the propensity score model 
 □ 15 Explain the variable selection procedure for propensity score model 
 □ 16 PSM: explicitly state the matching algorithm and distance metric, indicate 
matching ratio (1:m matching), indicate whether sampling with or without 
replacement was used, describe the statistical methods for the analysis of 
matched data, report the package used to create matched sample, and describe 
methods for assessing the comparability of baseline characteristics in the 
matched groups 
 □ 17 PSW: describe methods for assessing the comparability of baseline 
characteristics in the weighted groups 
 □ 18 PSS: give the number of strata and describe methods for assessing the 
comparability of baseline characteristics in each stratum 
 □ 19 Explain how assumption of propensity score analysis was examined 
 □ 20 Explain how missing data in propensity score estimation were addressed 
Results     
Participants □ 25.4 PSM: report the sample size for each treatment group before and after matching  
Patient 
characteristics 
□ 28 Describe the distribution of baseline characteristics for each group before 
propensity score analysis 
 □ 29 PSM, PSW, PSS: describe the distribution of baseline characteristics in the 
matched/weighted groups or in each stratum, and describe the results of the 
comparability of baseline characteristics 
 □ 30 Indicate number of patients with missing data for each variable of interest, 
especially the variables used in propensity score model 
Main results □ 32 Give propensity score analysis estimates and their precision, e.g. 95% 
confidence interval 
 □ 33 If applicable, give unadjusted estimates and/or adjusted estimates and their 
precision, e.g. 95% confidence interval. Make clear which additional factors 
were adjusted for 
Discussion    
Interpretation □ 38 Discuss whether imbalance of baseline characteristics still exists, and give a 
cautious interpretation 
Generalizability □ 40 PSM: discuss the possibility and potential influence of incomplete matching, 
especially the studies in which the matched sample size is less than 50% 
PSM = propensity score matching, PSW = propensity score weighting, PSS = propensity score stratification, CAPS = 
covariate adjustment using propensity score 
* For full guidelines, refer to the Supplementary Table S5 
 
 Figure 1 A 
 
Figure 1 B 
 
* Other reasons are given in Supplementary Table S1. 
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Supplementary Methods  
Top 10 general medical journals, top 15 cancer journals, and top 15 surgery journals, based on 
Web of Knowledge impact factors 2014 (http://admin-apps.webofknowledge.com/JCR/JCR) 
 
Top 10 general medical journals 
1 NEW ENGL J MED 
2 LANCET 
3 JAMA 
4 ANN INTERN MED 
5 BMJ 
6 ARCH INTERN MED 
7 PLOS MED 
8 JAMA INTERN MED 
9 BMC MED 
10 J CACHEXIA SARCOPENI 
 
Top 15 cancer journals 
1 CA-CANCER J CLIN 
2 NAT REV CANCER 
3 LANCET ONCOL 
4 CANCER CELL 
5 CANCER DISCOV 
6 J CLIN ONCOL 
7 NAT REV CLIN ONCOL 
8 J Natl Cancer Inst 
9 LEUKEMIA 
10 SEMIN CANCER BIOL 
11 CANCER RES 
12 CLIN CANCER RES 
13 ONCOGENE 
14 BBA-REV CANCER 
15 CANCER TREAT REV 
 
Top 15 surgery journals 
1 ANN SURG 
2 J NEUROL NEUROSUR PS 
3 J HEART LUNG TRANSPL 
4 AM J TRANSPLANT 
5 BRIT J SURG 
6 J BONE JOINT SURG AM 
7 AM J SURG PATHOL 
8 J AM COLL SURGEONS 
3 
 
9 ENDOSCOPY 
10 ARCH SURG-CHICAGO 
11 LIVER TRANSPLANT 
12 J THORAC CARDIOV SUR 
13 SURG OBES RELAT DIS 
14 JAMA SURG 
15 ANN SURG ONCOL 
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Supplementary Figures 
Supplementary Figure 1. Published surgical studies in cancer using propensity score analysis  
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Supplementary Figure 2. Publication trends of studies reporting use of propensity score 
analysis in cancer, cardiovascular disease, and diabetes 
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Supplementary Tables 
 
 
Supplementary Table 1. List of reasons for exclusion in the process of literature search of 
cancer surgical studies - The primary question did not involve surgery 
Primary question No. of Studies 
Health condition comparison (e.g. symptoms, co-existing other diseases, 
characteristics of cancer, severity) 
34 
Socio-demographic information comparison 20 
Drug efficacy 19 
Characteristics of hospital (e.g. hospital volume) 9 
Radiation 8 
Analgesia/anesthesia  7 
Blood transfusion  6 
Characteristics of medical practitioner (e.g. surgeon  specialization, surgeon 
volume, changing urologists)  
5 
Chemotherapy  5 
Diagnostic methods (e.g. CT, MRI)  5 
Hormone therapy  4 
The standard of care  4 
Implant  4 
Adherence to treatment guideline 3 
An oral enzyme 1 
Anal decompression  1 
Association between utility and treatment  1 
Length of interval 1 
Physiotherapy 1 
Preoperative mechanical bowel preparation  1 
Self-referral  1 
Skin closure methods  1 
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Supplementary Table 2. Completed PRISMA Checklist  
Section/topic  # Checklist item  
Reporte
d on 
page #  
TITLE   
Title  1 Identify the report as a systematic review, meta-analysis, or both.  1 
ABSTRACT   
Structured summary  2 Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility 
criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; 
conclusions and implications of key findings; systematic review registration number.  
2 
INTRODUCTION   
Rationale  3 Describe the rationale for the review in the context of what is already known.  3,4 
Objectives  4 Provide an explicit statement of questions being addressed with reference to participants, interventions, 
comparisons, outcomes, and study design (PICOS).  
4 
METHODS   
Protocol and registration  5 Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, 
provide registration information including registration number.  
no 
Eligibility criteria  6 Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years 
considered, language, publication status) used as criteria for eligibility, giving rationale.  
4,5 
Information sources  7 Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify 
additional studies) in the search and date last searched.  
4,5 
Search  8 Present full electronic search strategy for at least one database, including any limits used, such that it could be 
repeated.  
4,5 
Study selection  9 State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if 
applicable, included in the meta-analysis).  
4,5 
8 
 
Data collection process  10 Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any 
processes for obtaining and confirming data from investigators.  
5,6 
Data items  11 List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions 
and simplifications made.  
5,6 
Risk of bias in individual 
studies  
12 Describe methods used for assessing risk of bias of individual studies (including specification of whether this 
was done at the study or outcome level), and how this information is to be used in any data synthesis.  
N/A 
Summary measures  13 State the principal summary measures (e.g., risk ratio, difference in means).  7 
Synthesis of results  14 Describe the methods of handling data and combining results of studies, if done, including measures of 
consistency (e.g., I2) for each meta-analysis.  
7 
Section/topic  # Checklist item  Reporte
d on 
page #  
Risk of bias across studies  15 Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, 
selective reporting within studies).  
N/A 
Additional analyses  16 Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, 
indicating which were pre-specified.  
N/A 
RESULTS   
Study selection  17 Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for 
exclusions at each stage, ideally with a flow diagram.  
7; figure 
1  
Study characteristics  18 For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up 
period) and provide the citations.  
8,9 
Risk of bias within studies  19 Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).  N/A 
Results of individual 
studies  
20 For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each 
intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.  
9,10 
Synthesis of results  21 Present results of each meta-analysis done, including confidence intervals and measures of consistency.  N/A 
Risk of bias across studies  22 Present results of any assessment of risk of bias across studies (see Item 15).  N/A 
Additional analysis  23 Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 
16]).  
N/A 
DISCUSSION   
9 
 
Summary of evidence  24 Summarize the main findings including the strength of evidence for each main outcome; consider their 
relevance to key groups (e.g., healthcare providers, users, and policy makers).  
10-15 
Limitations  25 Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete 
retrieval of identified research, reporting bias).  
14 
Conclusions  26 Provide a general interpretation of the results in the context of other evidence, and implications for future 
research.  
14 
FUNDING   
Funding  27 Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders 
for the systematic review.  
15 
 
From:  Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(6): 
e1000097. doi:10.1371/journal.pmed1000097  
For more information, visit: www.prisma-statement.org.  
 
  
10 
 
 
Supplementary Table 3. The matched proportion of the targeted treatment group of included studies * 
Proportion 
Cancer Studies† Cancer Surgical Studies 
No. of Studies/Total No. (%) No. of Studies/Total No. (%) 
<25% 1/21 (4.8) 5/219 (2.3) 
25%-<50% 2/21 (9.5) 32/219 (14.6) 
50%-<75% 2/21 (9.5) 28/219 (12.8) 
75%-<100% 10/21 (47.6) 93/219 (42.5) 
Not mentioned 4/21 (19.0) 13/219 (5.9) 
Not evaluable‡ 2/21 (9.5) 23/219 (10.5) 
Only reported the matched sample 0 25/219 (11.4) 
* The reporting was evaluated in studies utilizing matching. Nine studies were included in both cancer studies and cancer surgical studies. 
† Cancer studies in top medical and cancer journals in 2014/15 
‡ The proportion was not evaluable if there is no clear definition of which arm is the targeted treatment group. 
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Supplementary Table 4. Study design and endpoint of included studies 
Variables 
Cancer Studies* Cancer Surgical Studies 
No. of Studies/Total No. (%) No. of Studies/Total No. (%) 
Study design 
  
Cohort 32/33 (97.0) 306/306 (100.0) 
Case-control 1/33 (3.0) 0 
Study endpoint   
Continuous outcome 1/33 (3.0) 39/306 (12.7) 
Dichotomous/discrete outcome 6/33 (18.2) 96/306 (31.4) 
Survival/time-to-event outcome 27/33 (81.8) 224/306 (73.2) 
* Cancer studies in top medical and cancer journals in 2014/15. Nine studies were included in both cancer studies and cancer surgical studies.
12 
 
Supplementary Table 5. Analysis of included studies 
Analysis used in: 
Cancer Studies* 
Cancer Surgical 
Studies 
No. of Studies/ 
Total No. (%) 
No. of Studies/ 
Total No. (%) 
Studies with continuous outcome N = 1 N = 39 
Independent sample test† 0 23/39 (59.0) 
Paired test‡ 0 9/39 (23.1) 
Linear regression 1/1 (100.0) 6/39 (15.4) 
Not reported 0 1/39 (2.6) 
Studies with dichotomous/discrete outcome N = 6 N = 96 
Independent sample test§ 0 27/96 (28.1) 
Paired test|| 0 12/96 (12.5) 
Logistic regression 6/6 (100.0) 56/96 (58.3) 
Not reported 0 1/96 (1.0) 
Studies with survival/time-to-event outcome N = 27 N = 224 
Log-rank test/Tarone-Ware test 2/27 (7.4) 55/224 (24.6) 
Cox regression/flexible parametric survival model 20/27 (74.1) 89/224 (39.7) 
Both log-rank test and Cox regression 4/27 (14.8) 72/224 (32.1) 
Competing risks regression 1/27 (3.7) 8/224 (3.6) 
* Cancer studies in top medical and cancer journals in 2014/15. Nine studies were included in both cancer studies and cancer surgical studies 
† e.g. unpaired t-tests and Mann-Whitney U test  
‡ e.g. paired t-tests and Wilcoxon signed-rank test  
§ e.g. chi-squared test and Fisher’s exact test  
|| e.g. McNemar’s test and Cochran's Q test  
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Supplementary Table 6. Full guidelines for reporting propensity score analysis, modified From the STROBE (STrengthening the 
Reporting of OBservational studies in Epidemiology) Statement* 
Section/topic Item No Recommendation 
Title and abstract □ 1 Indicate the use of propensity analysis with a commonly used term in the title or the abstract 
 □ 2 Provide in the abstract an informative and balanced summary of what was done and what was found 
Introduction     
Background/rationale □ 3 Explain the scientific background and rationale for the investigation being reported 
Objectives □ 4 State specific objectives, including any prespecified hypotheses 
Methods     
Setting □ 5 Describe the setting, locations, and relevant dates, including periods of recruitment, treatment, follow-up, and 
data collection 
Patient selection □ 6 Give the eligibility criteria, and the sources and methods of subject ascertainment and selection 
Variables □ 7 Clearly define all outcomes, treatments, predictors. Give diagnostic criteria, if applicable 
Data sources/ 
measurement 
□ 8 For each variable of interest, give sources of data and details of methods of assessment (measurement) 
Bias □ 9 Describe how propensity score analysis was used to address bias 
 □ 10 Describe any other methods to address potential sources of bias, e.g. sensitivity analysis 
Sample size □ 11 Explain how the study size was arrived at 
Statistical analyses □ 12 Describe all the analytic methods, including the propensity score methods, e.g. matching, weighting, 
stratification, or covariate adjustment using propensity score 
 □ 13 Indicate the model used to estimate propensity score, e.g. logistic model, boosting (meta-classifiers), decision 
trees 
 □ 14 State the variables included in the propensity score model 
 □ 15 Explain the variable selection procedure for propensity score model 
  16 For propensity score matching: 
 □ 16.1  Explicitly state the matching algorithm and distance metric 
 □ 16.2 Indicate matching ratio (1:m matching) 
 □ 16.3 Indicate whether sampling with or without replacement was used 
 □ 16.4 Describe the statistical methods for the analysis of matched data 
14 
 
 □ 16.5 Describe methods for assessing the comparability of baseline characteristics in the matched groups 
 □ 17 For propensity score weighting, describe methods for assessing the comparability of baseline characteristics in 
the weighted groups  
  18 For propensity score stratification: 
 □ 18.1  Give the number of strata 
 □ 18.2 Describe methods for assessing the comparability of baseline characteristics in each stratum 
 □ 19 Explain how assumption of propensity score analysis was examined 
 □ 20 Explain how missing data were addressed, including missing data in propensity score estimation 
 □ 21 If applicable, describe any methods used to examine subgroups and interactions 
 □ 22 Describe any sensitivity analyses 
 □ 23 Indicate the software used for analysis 
 □ 24 If applicable, report the package used to create matched sample, e.g. GMATCH macro in SAS, MatchIt 
package®, Optmatch package ® 
Results     
Participants  25 Report numbers of participants at each stage of study: 
 □ 25.1 sample size of patients potentially eligible 
 □ 25.2 sample size of patients confirmed eligible and included 
 □ 25.3 sample size of patients analyzed 
 □ 25.4 for propensity score matching, sample size for each treatment group before and after matching 
 □ 26 Explain reasons for exclusion at each stage 
 □ 27 Consider use of a flow diagram 
Patient characteristics □ 28 Describe the distribution of baseline characteristics for each group before propensity score analysis 
  29 For propensity score matching, weighting, or stratification: 
 □ 29.1 Desc Describe the distribution of baseline characteristics in the matched/weighted groups or in each stratum 
 □ 29.2 Describe the results of the comparability of baseline characteristics, whether there are still systematic 
differences between treatment groups 
 □ 30 Indicate number of patients with missing data for each variable of interest, especially the variables used 
in propensity score model 
Outcome data □ 31 Report outcomes of each treatment group 
Main results □ 32 Give propensity score analysis estimates and their precision, e.g. 95% confidence interval 
15 
 
 □ 33 If applicable, give unadjusted estimates and/or adjusted estimates and their precision, e.g. 95% confidence 
interval. Make clear which additional factors were adjusted for 
Other analyses □ 34 Report other analyses done, e.g. analyses of subgroups and interactions, and sensitivity analyses 
Discussion     
Key results □ 35 Summarize key results with reference to study objectives 
Limitations □ 36 Discuss limitations of the study, taking into account sources of potential bias or imprecision 
 □ 37 Discuss both direction and magnitude of any potential bias 
Interpretation □ 38 Discuss whether imbalance of baseline characteristics still exists, and give a cautious interpretation 
 □ 39 Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, 
results from similar studies, and other relevant evidence 
Generalizability □ 40 For propensity score matching, discuss the possibility and potential influence  of incomplete matching, 
especially the studies in which the matched sample size is less than 50% 
Other information     
Funding □ 41 Give the source of funding and the role of the funders for the present study and, if applicable, for the original 
study on which the present article is based 
* von Elm E, Altman DG, Egger M, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: 
guidelines for reporting observational studies. J Clin Epidemiol 2008;61(4):344-9. 
This guideline can be downloaded at: 
https://sites.duke.edu/xiaofeiwang/files/2017/03/Supplementary-Table-6.pdf 
 
